Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
61
KZIA Quote, Financials, Valuation and Earnings
Last price:
$13.30
Seasonality move
:
10.38%
Day range:
$10.00 - $13.44
52-week range:
$2.86 - $25.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
598.69x
P/B ratio:
2.19x
Volume:
266.4K
Avg. volume:
1.3M
1-year change:
-46.36%
Market cap:
$22.1M
Revenue:
$27.2K
EPS (TTM):
-$6.67
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Kazia Therapeutics Ltd. has 24.49% upside to fair value with a price target of $16.49 per share.
KZIA vs. S&P 500
-
Over the past 5 trading days, Kazia Therapeutics Ltd. has overperformed the S&P 500 by 3.59% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kazia Therapeutics Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kazia Therapeutics Ltd. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Kazia Therapeutics Ltd. reported revenues of --.
Earnings Growth
-
Kazia Therapeutics Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kazia Therapeutics Ltd. reported earnings per share of --.
Enterprise value:
9.7M
EV / Invested capital:
--
Price / LTM sales:
598.69x
EV / EBIT:
--
EV / Revenue:
0.47x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-106.28%
Net Income Margin (TTM):
--
Return On Equity:
-1083.16%
Return On Invested Capital:
-784.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2006-06-30 | 2007-06-30 | 2008-06-30 | 2007-06-30 | 2008-06-30 | |
| Income Statement | ||||||
| Revenue | $10.1M | $8.4M | -- | $2.8M | $2.7M | |
| Gross Profit | $5.5M | $2.5M | $2.4M | -- | -- | |
| Operating Income | -- | -$26.5M | -- | -$34M | -$34.2M | |
| EBITDA | -- | -$25.8M | -- | -$34M | -$34.2M | |
| Diluted EPS | -$118.40 | -$154.03 | -$178.74 | -$201.49 | -$216.67 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $7.1M | $4.1M | -- | |
| Total Assets | -- | -- | $18.6M | $14.4M | -- | |
| Current Liabilities | -- | -- | $5M | $17.2M | -- | |
| Total Liabilities | -- | -- | $10.6M | $21.1M | -- | |
| Total Equity | -- | -- | $8M | -$6.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.5M | -$12.8M | -$6.5M | -$9M | -$8.3M | |
| Cash From Investing | $1.7M | -- | -$1.2M | -- | $9.4K | |
| Cash From Financing | $2.5M | $22.5M | $4.6M | $17.3M | $12.2K | |
| Free Cash Flow | -$3.5M | -$12.8M | -$6.5M | -- | -- | |
KZIA
Sector
Market Cap
$22.1M
$28.4M
Price % of 52-Week High
52.17%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-48.1%
-1.32%
1-Year Price Total Return
-46.36%
-22.19%
Beta (5-Year)
1.672
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.32
200-day SMA
Buy
Level
$6.50
Bollinger Bands (100)
Buy
Level
6.79 - 9.25
Chaikin Money Flow
Sell
Level
-66.9M
20-day SMA
Buy
Level
$8.42
Relative Strength Index (RSI14)
Buy
Level
67.46
ADX Line
Buy
Level
29.46
Williams %R
Sell
Level
-13.2333
50-day SMA
Buy
Level
$7.67
MACD (12, 26)
Buy
Level
1.02
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
111.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-40.9053)
Sell
CA Score
(Annual)
Level (-10.8714)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (22.8998)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Stock Forecast FAQ
In the current month, KZIA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KZIA average analyst price target in the past 3 months is $16.49.
-
Where Will Kazia Therapeutics Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kazia Therapeutics Ltd. share price will rise to $16.49 per share over the next 12 months.
-
What Do Analysts Say About Kazia Therapeutics Ltd.?
Analysts are divided on their view about Kazia Therapeutics Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kazia Therapeutics Ltd. is a Sell and believe this share price will drop from its current level to $12.85.
-
What Is Kazia Therapeutics Ltd.'s Price Target?
The price target for Kazia Therapeutics Ltd. over the next 1-year time period is forecast to be $16.49 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KZIA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kazia Therapeutics Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of KZIA?
You can purchase shares of Kazia Therapeutics Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kazia Therapeutics Ltd. shares.
-
What Is The Kazia Therapeutics Ltd. Share Price Today?
Kazia Therapeutics Ltd. was last trading at $13.30 per share. This represents the most recent stock quote for Kazia Therapeutics Ltd.. Yesterday, Kazia Therapeutics Ltd. closed at $13.25 per share.
-
How To Buy Kazia Therapeutics Ltd. Stock Online?
In order to purchase Kazia Therapeutics Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KZIA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KZIA
Sector
P/E ratio
--
23.66x
PEG ratio
-0.02x
-0.01x
P/B ratio
2.19x
1.84x
Price / LTM sales
598.69x
1.60x
Growth Metrics
KZIA
Sector
Revenue growth
--
4.85%
Earnings growth
--
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.20
Profitability
KZIA
Sector
Profitability FY 2025
-$577.7K
$3.6M
Return on invested capital
-784.09%
-30.98%
Return on assets
-106.28%
-27.62%
Return on equity
-1083.16%
-36.69%
Earnings Date
Last Earnings Date
Dec
5
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
KZIA
Sector
Total cash
$1.1M
$27.2M
Short term investments
--
$25.7M
Total assets
$4M
$79.9M
Long term debt
$423.8K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
